Nycomed S.c.a. Sicar: Pharmavitae Profile - Market Research Reports On Aarkstore Enterprise

Introduction

Introduction

This analysis examines the historical and forecast performance for Nycomed in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Nycomed's performance against key rivals in the prescription pharmaceutical sector

*Determine the historical impact of M&A on Nycomed's specialty pharmaceutical business model

*Examine Nycomed's growth potential in the face of a blockbuster patent expiry

Table of Contents :

"ABOUT HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly news update 3

Company introduction 3

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 7

Nycomed: PharmaVitae forecasts at a glance 8

Strategic insight 9

Historical growth led by Altana acquisition 9

Near-term operating performance threatened by reduced pantoprazole sales 10

M&A extends geographical reach to global scale 10

SWOT analysis 11

Table of Contents 12

Table of figures 14

Chapter 3 Quarterly news update 15

Product developments 15

Deals and alliances 16

Product deals 16

Company announcements 17

Chapter 4 Company introduction 18

Key findings 18

Background 19

Key corporate developments 19

M&A history 20

Chapter 5 Company sales 22

Key findings 22

Prescription pharmaceutical sales and growth rate analysis, 2002-14 23

Product analysis 24

Product analysis, 2002-08 25

Product analysis, 2008-14 27

Therapy area analysis 30

Geographic analysis 32

Launch/core/expiry analysis 34

Explanation of launch/core/expiry analysis 34

Launch analysis, 2008-14 35

Core analysis, 2008-14 36

Expiry analysis, 2008-14 37

Launch/core/expiry configuration, 2008-14 38

Molecule type analysis 39

Externalization analysis 41

Chapter 6 Company financials 43

Key findings 43

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 44

Operating costs and profit analysis 45

Operating costs and profit analysis, 2002-08 46

Operating cost ratio and profit margin analysis, 2002-08 47

Operating cost ratio and profit margin analysis, 2008-14 48

Operating costs and profit analysis, 2008-14 49

Chapter 7 Key products and competitors 50

Key findings 50

Overview 51

Gastroenterology 52

Pantoprazole 52

Overview 52

Sales forecast 53

Sales remain strong despite generic encroachment in the US 54

Efficacy favors Protonix in an already genericized market 55

Respiratory 56

Alvesco 56

Overview 56

Sales forecast 57

New once-daily inhaled corticosteroid for asthma 57

US licensing agreement reached with respiratory specialist Sepracor 57

Asthma market overview 57

Ciclesonide safety advantages could help overcome barriers to uptake 58

Alvesco forecast assumptions 59

Omnaris 60

Overview 60

Sales forecast 61

Allergic rhinitis launch adds significant value to franchise 61

Daxas 62

Overview 62

Sales forecast 63

Commercial attractiveness 65

Genitourinary 66

Preotact 66

Overview 66

Sales forecast 67

Novel medication for high fracture risk postmenopausal osteoporosis 67

Preotact offers novel administration and MOA 67

Chapter 8 Appendix 69

R&D pipeline 69

References 70

Abbreviations 70

Exchange rates 72

About 73

About Healthcare 73

consulting 73

Disclaimer 75

List of Tables

Table 1: Nycomed - PharmaVitae forecasts at a glance 8

Table 2: Nycomed operating cost ratio analysis (% of total revenues), 2002-08 9

Table 3: Nycomed key product developments, 2009 15

Table 4: Nycomed product deals and alliances, 2009 16

Table 5: Nycomed company announcements, 2009 17

Table 6: Nycomed product portfolio overview ($m), 2002-08 25

Table 7: Nycomed product portfolio overview ($m), 2008-14 27

Table 8: Nycomed prescription pharmaceutical sales by therapy area ($m), 2008-14 31

Table 9: Nycomed prescription pharmaceutical sales by geographic region ($m), 2008-14 33

Table 10: Nycomed launch portfolio overview ($m), 2008-14 35

Table 11: Nycomed core portfolio overview ($m), 2008-14 36

Table 12: Nycomed expiry portfolio overview ($m), 2008-14 37

Table 13: Nycomed prescription pharmaceutical sales by molecule type ($m), 2008-14 40

Table 14: Nycomed prescription pharmaceutical sales by source ($m), 2008-14 42

Table 15: Total Nycomed sales by business unit ($m), 2002-08 44

Table 16: Nycomed operating revenue/cost analysis ($m), 2002-08 46

Table 17: Nycomed operating cost ratio analysis (% of total revenues), 2002-08 47

Table 18: Nycomed operating cost ratio analysis (% of total revenues), 2008-14 48

Table 19: Nycomed operating revenue/cost analysis ($m), 2008-14 49

Table 20: Key products overview 51

Table 21: Pantoprazole: overview 52

Table 22: Pantoprazole: sales forecast ($m), 2008-14 53

Table 23: Alvesco: overview 56

Table 24: Alvesco: sales forecast ($m), 2008-14 57

Table 25: Omnaris: overview 60

Table 26: Omnaris: sales forecast ($m), 2008-14 61

Table 27: Daxas: overview 62

Table 28: Daxas: sales forecast ($m), 2008-14 63

Table 29: Preotact: overview 66

Table 30: Preotact: sales forecast ($m), 2008-14 67

Table 31: Nycomed's R&D pipeline (Phase I-registration) 69

Table 32: Exchange rates, 2009 72

List of Figures

Figure 1: The PharmaVitae Explorer 3

Figure 2: Nycomed prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: Nycomed's financial performance ($m), 2002-14 7

Figure 4: Nycomed SWOT analysis 11

Figure 5: Nycomed prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 23

Figure 6: Key product sales ($m), 2002-14 24

Figure 7: Nycomed key sales growth drivers and resistors ($m), 2002-08 26

Figure 8: Nycomed key sales growth drivers and resistors ($m), 2008-14 28

Figure 9: Nycomed prescription pharmaceutical sales by therapy area ($m), 2002-14 30

Figure 10: Nycomed prescription pharmaceutical sales by geographic region ($m), 2002-14 32

Figure 11: Nycomed launch/core/expiry configuration ($m), 2008-14 38

Figure 12: Nycomed prescription pharmaceutical sales by molecule type ($m), 2002-14 39

Figure 13: Nycomed prescription pharmaceutical sales by source ($m), 2002-14 41

Figure 14: Nycomed operating revenue/cost analysis ($m), 2002-14 45

For more information please visit :

http://www.aarkstore.com/reports/Nycomed-S-C-A-SICAR-PharmaVitae-Profile-45160.html

by: Aarkstore Enterprise

POST COMMENT

The rechargeable battery on the market now turns out to be a wide range of brands are present Aarkstore Enterprise-global Biofuels Market: Opportunities, Emerging Technologies, Production 3 Things All Affiliate Marketers Need To Survive Online You Cannot Market A Website That Is Under Construction A Day In The Life Of An Affiliate Marketer Affiliate Marketing And Pay Per Click Affiliate Marketing Options The Diet Solution Program Scam - The Diet Solution Reviews Exposed Affiliate Marketing Resources Affiliate Marketing Rules Affiliate Marketing Tips Affiliate Marketing: Tips On How To Spot A Scam Affiliate Marketing: What Is It?